PreveCeutical Medical Announces Frontiers Media SA Publication Featuring Data from its Analgesic Program for the Treatment of Peptide-based Therapeutics for Moderate to Severe Pain
Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is pleased to announce the full independent peer-reviewed publication of an article on the design and development of its non-addictive
2023-04-04 7:00 AM EDT
PreveCeutical Initiates Non-Analgesic (Painkiller) Program, Clinical Development Program & Disclosure Committee
Vancouver, British Columbia--(Newsfile Corp. - March 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that PreveCeutical commenced clinical work with our selected clinical research organization (CRO) as announced on February 7, 2023, to complete the following. Conduct a comprehensive gap analysis to both confirm current conclusions as well as identify any potential additional nonclinical studies (beyond...
2023-03-20 7:00 AM EDT
PreveCeutical - International Filing of Thermoresponsive Sol-Gels Containing Cannabinoids & Uses Thereof
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that PreveCeutical is furthering the progress of its Sol-Gel Cannabinoid Therapies patent family based on International Patent Application PCT/IB2021/022211 (Thermoresponsive Sol-Gels containing cannabinoids), and is taking the International patent application forward in the US, Europe, Canada and Australia....
2023-03-06 7:00 AM EST
Appointment of C. Evan Ballantyne to PreveCeutical's Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces the appointment of Mr. Evan Ballantyne to the Company's board of directors (the "Board") effective February 17, 2023. Mr. Ballantyne has extensive executive leadership experience and has spent the last 20 years as a public and private company Chief Financial Officer in the healthcare industry. He was most recently the...
2023-02-21 7:00 AM EST
PreveCeutical Awards ICON Analgesic Program (Painkiller) Clinical Development
Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that on February 1, 2023, PreveCeutical has appointed ICON as the clinical research organization (CRO) to complete the following. Conduct a comprehensive gap analysis to both confirm current conclusions as well as identify any potential additional nonclinical studies (beyond those already underway or in...
2023-02-07 11:48 AM EST
PreveCeutical - Australian Patent Granted for Disulfide Bond Containing Compounds
Vancouver, British Columbia--(Newsfile Corp. - January 25, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the grant of Australian patent no. 2018305726, titled "Disulfide bond containing compounds and uses thereof," on January 5, 2023. The patent is owned by the University of Queensland (UQ) in Australia, and UniQuest (UQ's commercialization company) has licensed it exclusively to PreveCeutical. The...
2023-01-25 7:00 AM EST
PreveCeutical - Background IP, US Patent Granted Disulfide Bond Containing Compounds
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that US patent no. 11,566,044, titled 'Disulfide bond containing compounds and uses thereof', will be granted on January 31, 2023. The patent is owned by the University of Queensland (UQ) in Australia, and UniQuest (UQ's commercialization company) has granted PreveCeutical exclusive rights to the platform...
2023-01-23 7:00 AM EST
PreveCeutical - Dynorphin Peptides (Painkiller) and Uses Thereof Patent Update and Officer Update
Vancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that PreveCeutical is furthering the progress of its patent family directed to peptide analogues of dynorphin and their use in pain management (International Patent Application No. PCT/AU2021/050707, Peptides and Uses) and is taking the International patent application forward in the US, Europe, Canada...
2023-01-17 7:00 AM EST
PreveCeutical Enters into License Option Agreement with Endosane Pharmaceuticals
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has entered into a License Option Agreement with Endosane Pharmaceuticals GmbH ("Endosane"), a subsidiary of Sanity Group, dated January 10, 2023, pursuant to which Endosane has been granted an option to license the sol-gel technology for the delivery of cannabinoid products on an exclusive basis...
2023-01-12 6:00 AM EST
PreveCeutical Signs Intercompany Sol-Gel License Agreement
Vancouver, British Columbia--(Newsfile Corp. - January 9, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has entered into a license agreement with its subsidiary PreveCeutical (Australia) Pty Ltd. (the "Subsidiary" or "PAPL") for the exclusive rights to the Sol-Gel intellectual property and technology for the delivery of cannabinoids ("Sol-Gel License"). PAPL has an exclusive license agreement with...
2023-01-09 7:00 AM EST
PreveCeutical Files Application for D-amino Acid Peptides
Vancouver, British Columbia--(Newsfile Corp. - November 21, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a PCT (Patent Cooperation Treaty) application number PCT/IB2022/06117 on November 18, 2022, entitled "Peptides and Uses Thereof", with the aim of seeking protection for certain peptides comprising D-amino acids and their use in methods of treating brain cancer. This patent application is...
2022-11-21 8:00 AM EST
PreveCeutical Announces Conversion of Debt
Vancouver, British Columbia--(Newsfile Corp. - November 11, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has entered into an assignment agreement with a certain arm's length assignee (the "Assignee"). Per the assignment agreement, the Assignee acquired all of Stephen Van Deventer and Kimberly Van Deventer's rights, title, interests and obligations in and under a convertible credit facility agreement dated...
2022-11-11 7:30 PM EST
Appointment of Kathleen Rokita to PreveCeutical's Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - October 20, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , announces the appointment of Ms. Kathleen Rokita ("Kathy") to the Company's board of directors (the "Board"). Kathy is a CPA and Principal of Somerset CPA's P.C. She is a finance, operations, and strategy-focused executive with extensive experience with large medical groups. Her experience includes financial performance...
2022-10-20 8:00 AM EDT
PreveCeutical Announces Resignation of Board of Director Member
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the resignation of Mr. Sachin Nanavati as a member of the Company's board of director (the "Board") for personal reasons effective September 16, 2022. Stephen Van Deventer, PreveCeutical's Chief Executive Officer, commented, "We thank Mr. Nanavati for considering to be on the Company's Board and wish him all the...
2022-09-16 8:00 PM EDT
Appointment of Sachin Nanavati to PreveCeutical's Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - September 6, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the appointment of Mr. Sachin Nanavati to the Company's board of directors (the "Board") effective September 1, 2022. Sachin is currently the Head of Industry, Healthcare with Google, Inc. He has vast knowledge and experience with healthcare and technology. Sachin was a founding member of Meta (Facebook)'s Health...
2022-09-06 7:00 AM EDT
PreveCeutical Enters into Credit Facility Agreement
Vancouver, British Columbia--(Newsfile Corp. - July 22, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has entered into a $3 million credit facility agreement with the Company's Chief Executive Officer and Chair, Stephen Van Deventer, and the Company's former President and director, Kimberly Van Deventer (collectively, the "Lenders"). Effective July 18, 2022, the Company entered into a convertible credit facility...
2022-07-22 4:47 PM EDT
PreveCeutical Announces Change in Directors and Investor Awareness Services
Vancouver, British Columbia--(Newsfile Corp. - May 27, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the resignation of Mr. Anderson and Mr. Lotz and the appointment of Dr. Linnéa Olofsson to the Company's board of directors (the "Board"). Resignation of Directors Mr. Keith Anderson and Mr. Mark Lotz will be stepping down as directors of the Company effective May 31, 2022, to allow them more time to focus on their...
2022-05-27 4:30 PM EDT
Article Based on PreveCeutical's Pain Management Peptides Program Published in the British Journal of Pharmacology
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that the British Journal of Pharmacology (the "BJP"), published an article on April 29, 2022, on the design and development of its non-addictive analgesic program ("Analgesic Program") under the running title, "Short dynorphin-like peptide agonists for kappa opioid receptors" click here to see the report. The...
2022-05-09 8:00 AM EDT
PreveCeutical Announces Debt Settlement and Conversion of Debt
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that it has issued 11,600,000 common shares without par value in its capital (each, a "Share") to two non-arm's length creditors and an arm's length creditor of the Company at a deemed issuance price of $0.025 per Share. The Company entered into shares for debt settlement agreements with a current director and a company...
2022-03-30 8:00 PM EDT
Settlement Reached in Tietz Class Action Lawsuit
Vancouver, British Columbia--(Newsfile Corp. - January 13, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the settlement of the proposed class action filed by Michael Tietz and Duane Loewen against the Company and many other parties in B.C. Supreme Court Action No. S197731, Vancouver Registry (the "Action"). PreveCeutical commenced its own action against some of the defendants to the Action claiming damages...
2022-01-13 8:00 AM EST